Doxorubicin-induced cardiomyopathy from the cardiotoxic mechanisms to management.

[1]  W. Chan,et al.  Thrombopoietin Protects Against In Vitro and In Vivo Cardiotoxicity Induced by Doxorubicin , 2006, Circulation.

[2]  Y. Ru,et al.  Granulocyte Colony-Stimulating Factor Reduces Cardiomyocyte Apoptosis and Improves Cardiac Function in Adriamycin-Induced Cardiomyopathy in Rats , 2006, Cardiovascular Drugs and Therapy.

[3]  G. Takemura,et al.  Preventive Effect of Erythropoietin on Cardiac Dysfunction in Doxorubicin-Induced Cardiomyopathy , 2006, Circulation.

[4]  G. Takemura,et al.  Morphological aspects of apoptosis in heart diseases , 2006, Journal of cellular and molecular medicine.

[5]  P. Singal,et al.  Involvement of mitogen-activated protein kinases in adriamycin-induced cardiomyopathy. , 2005, American journal of physiology. Heart and circulatory physiology.

[6]  A. Lahiri,et al.  Clinical role of indium-111 antimyosin imaging , 2005, European Journal of Nuclear Medicine.

[7]  D. Alberts,et al.  Efficacy and safety of liposomal anthracyclines in phase I/II clinical trials. , 2004, Seminars in oncology.

[8]  P. Oliveira,et al.  Carvedilol-mediated antioxidant protection against doxorubicin-induced cardiac mitochondrial toxicity. , 2004, Toxicology and applied pharmacology.

[9]  L. Gianni,et al.  Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity , 2004, Pharmacological Reviews.

[10]  R. Schwartz,et al.  Essential role of GATA-4 in cell survival and drug-induced cardiotoxicity. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[11]  Roelof J Bennink,et al.  Annexin V imaging of acute doxorubicin cardiotoxicity (apoptosis) in rats. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[12]  Fuminori Tsuruta,et al.  JNK promotes Bax translocation to mitochondria through phosphorylation of 14‐3‐3 proteins , 2004, The EMBO journal.

[13]  K. Kelly,et al.  Antioxidants and cancer therapy: a systematic review. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  Joy Joseph,et al.  Doxorubicin-induced apoptosis: Implications in cardiotoxicity , 2002, Molecular and Cellular Biochemistry.

[15]  P. Singal,et al.  Early changes in myocardial antioxidant enzymes in rats treated with adriamycin , 2001, Molecular and Cellular Biochemistry.

[16]  P. Singal,et al.  Adriamycin-induced heart failure: mechanisms and modulation , 2000, Molecular and Cellular Biochemistry.

[17]  S. Hughes.  Detection of apoptosis using in situ markers for DNA strand breaks in the failing human heart. Fact or epiphenomenon? , 2003, The Journal of pathology.

[18]  A. Ali,et al.  New aspects in probucol cardioprotection against doxorubicin-induced cardiotoxicity , 2003, Cancer Chemotherapy and Pharmacology.

[19]  S. Swain,et al.  Congestive heart failure in patients treated with doxorubicin , 2003, Cancer.

[20]  J. Groves,et al.  Potent Metalloporphyrin Peroxynitrite Decomposition Catalyst Protects Against the Development of Doxorubicin-Induced Cardiac Dysfunction , 2003, Circulation.

[21]  G. Takemura,et al.  Myocytes positive for in situ markers for DNA breaks in human hearts which are hypertrophic, but neither failed nor dilated: a manifestation of cardiac hypertrophy rather than failure , 2003, The Journal of pathology.

[22]  Yuichiro J Suzuki,et al.  Anthracycline-induced suppression of GATA-4 transcription factor: implication in the regulation of cardiac myocyte apoptosis. , 2003, Molecular pharmacology.

[23]  A. Moreno,et al.  Carvedilol protects against doxorubicin-induced mitochondrial cardiomyopathy. , 2002, Toxicology and applied pharmacology.

[24]  X. Thomas,et al.  Anthracycline-related toxicity requiring cardiac transplantation in long-term disease-free survivors with acute promyelocytic leukemia , 2002, Annals of Hematology.

[25]  E. Winer,et al.  2002 update of recommendations for the use of chemotherapy and radiotherapy protectants: clinical practice guidelines of the American Society of Clinical Oncology. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  Theo Wallimann,et al.  Multiple interference of anthracyclines with mitochondrial creatine kinases: preferential damage of the cardiac isoenzyme and its implications for drug cardiotoxicity. , 2002, Molecular pharmacology.

[27]  J. Bauer,et al.  Intracellular distribution of peroxynitrite during doxorubicin cardiomyopathy: evidence for selective impairment of myofibrillar creatine kinase , 2002, British journal of pharmacology.

[28]  Afshin Samali,et al.  Losing heart: the role of apoptosis in heart disease—a novel therapeutic target? , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[29]  J. Joseph,et al.  Doxorubicin-induced Apoptosis Is Associated with Increased Transcription of Endothelial Nitric-oxide Synthase , 2001, The Journal of Biological Chemistry.

[30]  P. Morandi,et al.  Serum cardiac troponin I levels and ECG/Echo monitoring in breast cancer patients undergoing high-dose (7 g/m2) cyclophosphamide , 2001, Bone Marrow Transplantation.

[31]  H. Hayakawa,et al.  Plasma levels of natriuretic peptides in relation to doxorubicin-induced cardiotoxicity and cardiac function in children with cancer. , 2001, Medical and pediatric oncology.

[32]  S. Groshen,et al.  Phase I trial of 96-hour continuous infusion of dexrazoxane in patients with advanced malignancies. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[33]  G. Kroemer,et al.  Cell type specific involvement of death receptor and mitochondrial pathways in drug-induced apoptosis , 2001, Oncogene.

[34]  J. Joseph,et al.  Doxorubicin-induced Apoptosis in Endothelial Cells and Cardiomyocytes Is Ameliorated by Nitrone Spin Traps and Ebselen , 2000, The Journal of Biological Chemistry.

[35]  Y. Rojanasakul,et al.  Vanadate Induces p53 Transactivation through Hydrogen Peroxide and Causes Apoptosis* , 2000, The Journal of Biological Chemistry.

[36]  Xianglin Shi,et al.  The role of hydroxyl radical as a messenger in Cr(VI)-induced p53 activation. , 2000, American journal of physiology. Cell physiology.

[37]  C. Klersy,et al.  Lack of clinically significant cardiac dysfunction during intermediate dobutamine doses in long-term childhood cancer survivors exposed to anthracyclines. , 2000, American heart journal.

[38]  J. Bauer,et al.  Cardiac peroxynitrite formation and left ventricular dysfunction following doxorubicin treatment in mice. , 2000, The Journal of pharmacology and experimental therapeutics.

[39]  P. Kang,et al.  Apoptosis and heart failure: A critical review of the literature. , 2000, Circulation research.

[40]  J. Schaper,et al.  Unresolved issues regarding the role of apoptosis in the pathogenesis of ischemic injury and heart failure. , 2000, Journal of molecular and cellular cardiology.

[41]  R. Virmani,et al.  Apoptosis and cardiomyopathy. , 2000, Current opinion in cardiology.

[42]  A. Saraste,et al.  Acute doxorubicin cardiotoxicity involves cardiomyocyte apoptosis. , 2000, Cancer research.

[43]  K. Maehara,et al.  Apoptosis in relevant clinical situations: contribution of apoptosis in myocardial infarction. , 2000, Cardiovascular research.

[44]  R. Sung,et al.  A LONGITUDINAL STUDY OF CARDIAC FUNCTION IN CHILDREN WITH CANCER OVER 40 MONTHS , 2000, Pediatric hematology and oncology.

[45]  D. Green,et al.  Cancer and cardiac mortality among 15-year survivors of cancer diagnosed during childhood or adolescence. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  B. Kalyanaraman,et al.  Cell-permeable superoxide dismutase and glutathione peroxidase mimetics afford superior protection against doxorubicin-induced cardiotoxicity: the role of reactive oxygen and nitrogen intermediates. , 1999, Archives of biochemistry and biophysics.

[47]  K. Okumura,et al.  Protective effects of carvedilol against doxorubicin-induced cardiomyopathy in rats. , 1999, Life sciences.

[48]  R. Virmani,et al.  Apoptosis in heart failure: release of cytochrome c from mitochondria and activation of caspase-3 in human cardiomyopathy. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[49]  T. Aoyama,et al.  Significance of myocytes with positive DNA in situ nick end-labeling (TUNEL) in hearts with dilated cardiomyopathy: not apoptosis but DNA repair. , 1999, Circulation.

[50]  P. Ortiz de Montellano,et al.  Nitric oxide synthases catalyze the activation of redox cycling and bioreductive anticancer agents. , 1999, Cancer research.

[51]  D. Gewirtz,et al.  A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. , 1999, Biochemical pharmacology.

[52]  M. Hentze,et al.  Inactivation of Both RNA Binding and Aconitase Activities of Iron Regulatory Protein-1 by Quinone-induced Oxidative Stress* , 1999, The Journal of Biological Chemistry.

[53]  D. Sawyer,et al.  Daunorubicin-induced apoptosis in rat cardiac myocytes is inhibited by dexrazoxane. , 1999, Circulation research.

[54]  E. Monti,et al.  Role of iron in anthracycline cardiotoxicity: new tunes for an old song? , 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[55]  G. Hortobagyi,et al.  Doxorubicin-induced congestive heart failure in elderly patients with metastatic breast cancer, with long-term follow-up: the M.D. Anderson experience , 1999, Cancer Chemotherapy and Pharmacology.

[56]  P. Singal,et al.  Doxorubicin-induced cardiomyopathy. , 1998, The New England journal of medicine.

[57]  Lei Wang,et al.  Regulation of cardiomyocyte apoptotic signaling by insulin-like growth factor I. , 1998, Circulation research.

[58]  B. Biondi,et al.  Doxorubicin‐induced cardiomyopathy treated with carvedilol , 1998, Clinical cardiology.

[59]  R. Nagai,et al.  Elevated B-type natriuretic peptide levels after anthracycline administration. , 1998, American heart journal.

[60]  T. Yue,et al.  Novel mechanisms in the treatment of heart failure: inhibition of oxygen radicals and apoptosis by carvedilol. , 1998, Progress in cardiovascular diseases.

[61]  S. Izumo,et al.  Apoptosis: basic mechanisms and implications for cardiovascular disease. , 1998, Circulation research.

[62]  R. Davis,et al.  In vivo detection and imaging of phosphatidylserine expression during programmed cell death. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[63]  S. Chen,et al.  ARC, an inhibitor of apoptosis expressed in skeletal muscle and heart that interacts selectively with caspases. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[64]  S. Nagata,et al.  A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD , 1998, Nature.

[65]  P. Singal,et al.  Adriamycin cardiomyopathy: pathophysiology and prevention , 1997, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[66]  K. Pritchard,et al.  Endothelial nitric oxide synthase-dependent superoxide generation from adriamycin. , 1997, Biochemistry.

[67]  W. MacLellan,et al.  Death by design. Programmed cell death in cardiovascular biology and disease. , 1997, Circulation research.

[68]  S. Srinivasula,et al.  FLAME-1, a Novel FADD-like Anti-apoptotic Molecule That Regulates Fas/TNFR1-induced Apoptosis* , 1997, The Journal of Biological Chemistry.

[69]  Guy S. Salvesen,et al.  X-linked IAP is a direct inhibitor of cell-death proteases , 1997, Nature.

[70]  M. Davies.  Apoptosis in cardiovascular disease. , 1997, Heart.

[71]  W Stremmel,et al.  Differences in the Regulation of Iron Regulatory Protein-1 (IRP-1) by Extra- and Intracellular Oxidative Stress* , 1997, The Journal of Biological Chemistry.

[72]  L. Peng,et al.  Regulation of the rat cardiac troponin I gene by the transcription factor GATA-4. , 1997, The Biochemical journal.

[73]  Minoru Takagi,et al.  Induction of Apoptosis by ASK1, a Mammalian MAPKKK That Activates SAPK/JNK and p38 Signaling Pathways , 1997, Science.

[74]  P. Hornsby,et al.  Presence of double-strand breaks with single-base 3' overhangs in cells undergoing apoptosis but not necrosis , 1996, The Journal of cell biology.

[75]  N Sarvazyan,et al.  Visualization of doxorubicin-induced oxidative stress in isolated cardiac myocytes. , 1996, The American journal of physiology.

[76]  A. Serafini,et al.  Review of tests for monitoring doxorubicin-induced cardiomyopathy. , 1996, Oncology.

[77]  S. Ménard,et al.  Apoptosis of hair follicle cells during doxorubicin-induced alopecia in rats. , 1996, Laboratory investigation; a journal of technical methods and pathology.

[78]  V. Ferrans,et al.  Doxorubicin-induced apoptosis in spontaneously hypertensive rats: differential effects in heart, kidney and intestine, and inhibition by ICRF-187. , 1996, Journal of molecular and cellular cardiology.

[79]  R. Klausner,et al.  Iron-sulfur clusters as biosensors of oxidants and iron. , 1996, Trends in biochemical sciences.

[80]  A. Bast,et al.  Doxorubicin-induced cardiotoxicity monitored by ECG in freely moving mice A new model to test potential protectors , 1996, Cancer Chemotherapy and Pharmacology.

[81]  Michael E. Greenberg,et al.  Opposing Effects of ERK and JNK-p38 MAP Kinases on Apoptosis , 1995, Science.

[82]  D. Nowak,et al.  Ambroxol inhibits doxorubicin-induced lipid peroxidation in heart of mice. , 1995, Free radical biology & medicine.

[83]  John A. Murphy,et al.  Reactions of oxyl radicals with DNA. , 1995, Free radical biology & medicine.

[84]  M. Hentze,et al.  Rapid responses to oxidative stress mediated by iron regulatory protein. , 1995, The EMBO journal.

[85]  Arul M. Chinnaiyan,et al.  FADD, a novel death domain-containing protein, interacts with the death domain of fas and initiates apoptosis , 1995, Cell.

[86]  P. Singal,et al.  Combination therapy with probucol prevents adriamycin-induced cardiomyopathy. , 1995, Journal of molecular and cellular cardiology.

[87]  N. Singh,et al.  Induction of apoptosis in chronic myelogenous leukemia lymphocytes by hydroxyurea and adriamycin. , 1995, Cancer letters.

[88]  P. Singal,et al.  Probucol protects against adriamycin cardiomyopathy without interfering with its antitumor effect. , 1995, Circulation.

[89]  E. A. Martins,et al.  Oxidative stress induces activation of a cytosolic protein responsible for control of iron uptake. , 1995, Archives of biochemistry and biophysics.

[90]  D. Renlund,et al.  Efficacy and safety of metoprolol in the treatment of doxorubicin-induced cardiomyopathy in pediatric patients. , 1995, American heart journal.

[91]  E. Monti,et al.  Free radical-dependent DNA lesions are involved in the delayed cardiotoxicity induced by adriamycin in the rat. , 1995, Anticancer research.

[92]  D. Thompson,et al.  Dexrazoxane in the Prevention of Doxorubicin-Induced Cardiotoxicity , 1994, The Annals of pharmacotherapy.

[93]  C. Reutelingsperger,et al.  Expression on B Cells Undergoing Apoptosis Annexin V for Flow Cytometric Detection of Phosphatidylserine , 2022 .

[94]  J. Molkentin,et al.  Transcription factor GATA-4 regulates cardiac muscle-specific expression of the alpha-myosin heavy-chain gene , 1994, Molecular and cellular biology.

[95]  P. Singal,et al.  Probucol promotes endogenous antioxidants and provides protection against adriamycin-induced cardiomyopathy in rats. , 1994, Circulation.

[96]  A. Składanowski,et al.  Adriamycin and daunomycin induce programmed cell death (apoptosis) in tumour cells. , 1993, Biochemical pharmacology.

[97]  A. Fischman,et al.  Metaiodobenzylguanidine: evaluation of its potential as a tracer for monitoring doxorubicin cardiomyopathy. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[98]  A. Fischman,et al.  Myocardial substrate utilization and left ventricular function in adriamycin cardiomyopathy. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[99]  D. Carson,et al.  Apoptosis and disease , 1993, The Lancet.

[100]  R. Klausner,et al.  Regulating the fate of mRNA: The control of cellular iron metabolism , 1993, Cell.

[101]  R. Weiss.  The anthracyclines: will we ever find a better doxorubicin? , 1992, Seminars in oncology.

[102]  S. Balanehru,et al.  Intervention of adriamycin induced free radical damage. , 1992, Biochemistry international.

[103]  F. Marumo,et al.  Myocardial Uptake of 111In Monoclonal Antimyosin Fab in Detecting Doxorubicin Cardiotoxicity in Rats: Morphological and Hemodynamic Findings , 1992, Circulation.

[104]  S. Ben‐Sasson,et al.  Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation , 1992, The Journal of cell biology.

[105]  D. Gustafson,et al.  PZ-51 (Ebselen) in vivo protection against adriamycin-induced mouse cardiac and hepatic lipid peroxidation and toxicity. , 1992, Biochemical pharmacology.

[106]  M. Turina,et al.  Orthotopic heart transplantation: an efficient treatment in a young boy with doxorubicin-induced cardiomyopathy. , 1992, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[107]  A. Benson,et al.  Biochemical determinants of Adriamycin toxicity in mouse liver, heart and intestine. , 1992, Biochemical pharmacology.

[108]  M. Shamoto,et al.  Ascorbic acid and adriamycin toxicity. , 1991, The American journal of clinical nutrition.

[109]  P. Narang,et al.  Toxicity profile of dexrazoxane (Zinecard, ICRF-187, ADR-529, NSC-169780), a modulator of doxorubicin cardiotoxicity. , 1991, Cancer treatment reviews.

[110]  P. Singal,et al.  Myocardial adrenergic changes at two stages of heart failure due to adriamycin treatment in rats. , 1991, The American journal of physiology.

[111]  J. Cohen,et al.  Programmed cell death in the immune system. , 1991, Advances in immunology.

[112]  I. Carrió,et al.  Indium-111-antimyosin scintigraphy after doxorubicin therapy in patients with advanced breast cancer. , 1990, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[113]  V. Ferrans,et al.  Antitumor activity of liposome-encapsulated doxorubicin in advanced breast cancer: phase II study. , 1990, Journal of the National Cancer Institute.

[114]  H. Imura,et al.  Increased human brain natriuretic peptide in congestive heart failure. , 1990, The New England journal of medicine.

[115]  C. Winterbourn,et al.  dl-N,N'-dicarboxamidomethyl-N,N'-dicarboxymethyl-1,2-diaminopropane (ICRF-198) and d-1,2-bis(3,5-dioxopiperazine-1-yl)propane (ICRF-187) inhibition of Fe3+ reduction, lipid peroxidation, and CaATPase inactivation in heart microsomes exposed to adriamycin. , 1990, Cancer research.

[116]  M. Lishner,et al.  Reduced cardiotoxicity of doxorubicin by a 6‐hour infusion regimen. A prospective randomized evaluation , 1990, Cancer.

[117]  P. Riesz,et al.  Free radicals induced by adriamycin-sensitive and adriamycin-resistant cells: a spin-trapping study. , 1989, Biochemistry.

[118]  S. Bielack,et al.  Doxorubicin: effect of different schedules on toxicity and anti-tumor efficacy. , 1989, European journal of cancer & clinical oncology.

[119]  D. Botstein,et al.  DNA topoisomerase II must act at mitosis to prevent nondisjunction and chromosome breakage , 1989, Molecular and cellular biology.

[120]  F. Zunino,et al.  Formation, resealing and persistence of DNA breaks produced by 4-demethoxydaunorubicin in P388 leukemia cells. , 1989, Chemico-biological interactions.

[121]  F. Bonetti,et al.  Heart transplantation in a child with doxorubicin-induced cardiomyopathy. , 1988, The New England journal of medicine.

[122]  V. Ferrans,et al.  Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer. , 1988, The New England journal of medicine.

[123]  J. Lankelma,et al.  The role of oxygen-derived free radicals in the cytotoxicity of doxorubicin in multidrug resistant and sensitive human ovarian cancer cells. , 1988, Cancer letters.

[124]  J. Konopa.  G2 block induced by DNA crosslinking agents and its possible consequences. , 1988, Biochemical pharmacology.

[125]  V. Malatesta,et al.  Direct detection of paramagnetic species in adriamycin perfused rat hearts. , 1988, Biochemical and biophysical research communications.

[126]  J. Sisson,et al.  Metaiodobenzylguanidine as an index of the adrenergic nervous system integrity and function. , 1987, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[127]  P. Singal,et al.  Subcellular effects of adriamycin in the heart: a concise review. , 1987, Journal of molecular and cellular cardiology.

[128]  G. Batist,et al.  Differential formation of hydroxyl radicals by adriamycin in sensitive and resistant MCF-7 human breast tumor cells: implications for the mechanism of action. , 1987, Biochemistry.

[129]  P. Sager,et al.  Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Seven-year experience using serial radionuclide angiocardiography. , 1987, The American journal of medicine.

[130]  G. Batist,et al.  Adriamycin-stimulated hydroxyl radical formation in human breast tumor cells. , 1987, Biochemical pharmacology.

[131]  K. Wassermann,et al.  The effect of vitamin E and selenium on doxorubicin (Adriamycin) induced delayed toxicity in mice. , 2009, Acta pharmacologica et toxicologica.

[132]  Z. Kawakami,et al.  Prevention of doxorubicin myocardial toxicity in mice by reduced glutathione. , 1986, Cancer research.

[133]  G. Reeder,et al.  Atrial natriuretic peptide elevation in congestive heart failure in the human. , 1986, Science.

[134]  J. Doroshow,et al.  Redox cycling of anthracyclines by cardiac mitochondria. I. Anthracycline radical formation by NADH dehydrogenase. , 1986, The Journal of biological chemistry.

[135]  P. Singal,et al.  Adriamycin stimulates low-affinity Ca2+ binding and lipid peroxidation but depresses myocardial function. , 1986, The American journal of physiology.

[136]  M. Piver,et al.  Doxorubicin hydrochloride (adriamycin) cardiotoxicity evaluated by sequential radionuclide angiocardiography , 1985, Cancer.

[137]  N. Dubin,et al.  Prospective evaluation of cardiotoxicity during a six-hour doxorubicin infusion regimen in women with adenocarcinoma of the breast. , 1985, The American journal of medicine.

[138]  Singh Rp,et al.  Changes in lysosomal morphology and enzyme activities during the development of adriamycin-induced cardiomyopathy. , 1985 .

[139]  Paul J Thornalley,et al.  Free radical production from normal and adriamycin-treated rat cardiac sarcosomes. , 1985, Biochemical pharmacology.

[140]  L. Gianni,et al.  Thiol-dependent DNA damage produced by anthracycline-iron complexes. The structure-activity relationships and molecular mechanisms. , 1985, Molecular pharmacology.

[141]  V. Ferrans,et al.  Comparison of the effectiveness of (+/-)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187) and N-acetylcysteine in preventing chronic doxorubicin cardiotoxicity in beagles. , 1985, Cancer research.

[142]  M. Israel,et al.  Two mechanisms of adriamycin-DNA interaction in L1210 cells. , 1984, Biochemical pharmacology.

[143]  C. Myers,et al.  Hydroxyl radical production and DNA damage induced by anthracycline‐iron complex , 1984, FEBS letters.

[144]  L. Gianni,et al.  Oxidative destruction of DNA by the adriamycin-iron complex. , 1984, Biochemistry.

[145]  P. Singal,et al.  Direct effects of adriamycin on the rat heart sarcolemma. , 1984, Research communications in chemical pathology and pharmacology.

[146]  F. Torti,et al.  Reduced cardiotoxicity of doxorubicin delivered on a weekly schedule. Assessment by endomyocardial biopsy. , 1983, Annals of internal medicine.

[147]  M. Goris,et al.  Sensitivity and specificity of radionuclide ejection fractions in doxorubicin cardiotoxicity. , 1983, American heart journal.

[148]  T. Krugh,et al.  Adriamycin and daunorubicin bind in a cooperative manner to deoxyribonucleic acid. , 1983, Biochemistry.

[149]  R. Bonow,et al.  A randomized controlled trial assessing the prevention of doxorubicin cardiomyopathy by N-acetylcysteine. , 1983 .

[150]  J. Doroshow.  Effect of anthracycline antibiotics on oxygen radical formation in rat heart. , 1983, Cancer research.

[151]  J. Mason,et al.  Efficacy and cost of cardiac monitoring in patients receiving doxorubicin , 1982, Cancer.

[152]  R. Friedman,et al.  Nuclear catalyzed antibiotic free radical formation. , 1982, Cancer research.

[153]  S. Wallace,et al.  Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. , 1982, Annals of internal medicine.

[154]  J. Mason,et al.  Dose-effect and structure-function relationships in doxorubicin cardiomyopathy. , 1981, American heart journal.

[155]  V. Ferrans,et al.  Reduction of chronic doxorubicin cardiotoxicity in dogs by pretreatment with (+/-)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187). , 1981, Cancer research.

[156]  W. Haseltine,et al.  Reduction of adriamycin to a semiquinone-free radical by NADPH cytochrome P-450 reductase produces DNA cleavage in a reaction mediated by molecular oxygen. , 1981, The Journal of biological chemistry.

[157]  Michael V. Green,et al.  Doxorubicin cardiotoxicity: assessment of late left ventricular dysfunction by radionuclide cineangiography. , 1981, Annals of internal medicine.

[158]  D. V. Von Hoff,et al.  Phase I study of ICRF-187 using a daily for 3 days schedule. , 1981, Cancer treatment reports.

[159]  R D Olson,et al.  Regulatory role of glutathione and soluble sulfhydryl groups in the toxicity of adriamycin. , 1980, The Journal of pharmacology and experimental therapeutics.

[160]  R. Kernoff,et al.  Acute and Chronic Cardiovascular Effects of Doxorubicin in the Dog: The Cardiovascular Pharmacology of Drug‐Induced Histamine Release , 1980, Journal of cardiovascular pharmacology.

[161]  R. Mason,et al.  Spin-trapping and direct electron spin resonance investigations of the redox metabolism of quinone anticancer drugs. , 1980, Biochimica et biophysica acta.

[162]  A. Wyllie.  Glucocorticoid-induced thymocyte apoptosis is associated with endogenous endonuclease activation , 1980, Nature.

[163]  V. Ferrans,et al.  Cardiac disease induced by chronic adriamycin administration in dogs and an evaluation of vitamin E and selenium as cardioprotectants. , 1980, The American journal of pathology.

[164]  J. Doroshow,et al.  Enzymatic defenses of the mouse heart against reactive oxygen metabolites: alterations produced by doxorubicin. , 1980, The Journal of clinical investigation.

[165]  C. Chignell,et al.  Binding mode of chemically activated semiquinone free radicals from quinone anticancer agents to DNA. , 1979, Chemico-biological interactions.

[166]  J. Doroshow,et al.  The effect of doxorubicin on hepatic and cardiac glutathione. , 1979, Research communications in chemical pathology and pharmacology.

[167]  D. V. Von Hoff,et al.  Risk factors for doxorubicin-induced congestive heart failure. , 1979, Annals of internal medicine.

[168]  B. Sikic,et al.  The effects of α-tocopherol on the toxicity, disposition, and metabolism of adriamycin in mice , 1979 .

[169]  L. Goldman,et al.  Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiocardiography. , 1979, The New England journal of medicine.

[170]  N. Bachur,et al.  NADPH cytochrome P-450 reductase activation of quinone anticancer agents to free radicals. , 1979, Proceedings of the National Academy of Sciences of the United States of America.

[171]  E. Arena,et al.  Repair kinetics of DNA, RNA and proteins in the tissues of mice treated with doxorubicin. , 1979, Arzneimittel-Forschung.

[172]  G. van Rossum,et al.  Inhibition of sodium-potassium-activated adenosine 5'-triphosphatase and ion transport by adriamycin. , 1979, Cancer research.

[173]  Randolph P. Martin,et al.  Early anthracycline cardiotoxicity. , 1978, The American journal of medicine.

[174]  J. Mason,et al.  Anthracycline cardiomyopathy monitored by morphologic changes. , 1978, Cancer treatment reports.

[175]  J. Mason,et al.  Invasive and noninvasive methods of assessing adriamycin cardiotoxic effects in man: superiority of histopathologic assessment using endomyocardial biopsy. , 1978, Cancer treatment reports.

[176]  Daniels,et al.  Clinical spectrum of anthracycline antibiotic cardiotoxicity. , 1978, Cancer treatment reports.

[177]  I. Ifrim,et al.  Adriamycin: the role of lipid peroxidation in cardiac toxicity and tumor response. , 1977, Science.

[178]  J. Mason,et al.  Adriamycin cardiotoxicity: Endomyocardial biopsy evidence of enhancement by irradiation , 1977, The American journal of surgical pathology.

[179]  D. V. Von Hoff,et al.  Daunomycin-induced cardiotoxicity in children and adults. A review of 110 cases. , 1977, The American journal of medicine.

[180]  S. Sternberg,et al.  The cardiotoxicity of adriamycin and daunomycin in children , 1976, Cancer.

[181]  R. Reagan,et al.  Electrolyte and morphologic alterations of myocardium in adriamycin-treated rabbits. , 1974, The American journal of pathology.

[182]  W. Roberts,et al.  Cardiac ultrastructural changes induced by daunorubicin therapy , 1973, Cancer.

[183]  J. Pitha,et al.  A clinicopathologic analysis of adriamycin cardiotoxicity , 1973, Cancer.

[184]  A. Wyllie,et al.  Apoptosis: A Basic Biological Phenomenon with Wide-ranging Implications in Tissue Kinetics , 1972, British Journal of Cancer.

[185]  E. Herman,et al.  A comparison of the cardiovascular actions of daunomycin, adriamycin and N-acetyldaunomycin in hamsters and monkeys. , 1971, Pharmacology.